Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Studie av BDTX-1535, hos deltakere med glioblastom eller ikke-småcellet lungekreft

13. november 2026 oppdatert av: Black Diamond Therapeutics, Inc.

En fase 1-studie for å vurdere BDTX-1535, en oral EGFR-hemmer, hos deltakere med glioblastom eller ikke-småcellet lungekreft

BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles.

Phase 1 enrollment is now complete. Phase 2 is currently ongoing.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

220

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 4E6
    • Ontario
      • Toronto, Ontario, Canada, M5G 1X5
        • Rekruttering
        • The Princess Margaret Cancer Centre
        • Ta kontakt med:
    • Alabama
      • Birmingham, Alabama, Forente stater, 35294
        • Rekruttering
        • University of Alabama
        • Ta kontakt med:
    • Arizona
      • Gilbert, Arizona, Forente stater, 85234
    • California
      • Irvine, California, Forente stater, 92618
        • Rekruttering
        • City of Hope Orange County Lennar Foundation Cancer Center
        • Ta kontakt med:
          • Telefonnummer: 626-218-1133
        • Ta kontakt med:
          • Diana Patterson
          • Telefonnummer: 949-671-4763
      • Los Angeles, California, Forente stater, 90048
        • Rekruttering
        • Cedars Sinai Medical Center
        • Ta kontakt med:
    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20016
    • Florida
      • Jacksonville, Florida, Forente stater, 32224
        • Rekruttering
        • Mayo Clinic- Jacksonville
        • Ta kontakt med:
          • Yanyan Lou
          • Telefonnummer: 855-776-0015
      • Miami, Florida, Forente stater, 33176
        • Rekruttering
        • Miami Cancer Institute - Baptist Health South Florida
        • Ta kontakt med:
    • Hawaii
      • Honolulu, Hawaii, Forente stater, 96813
        • Rekruttering
        • UHP- University of Hawaii Cancer Center
        • Ta kontakt med:
          • Evan Wu, MD
          • Telefonnummer: 808-586-3010
    • Illinois
      • Chicago, Illinois, Forente stater, 60611
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02115
    • Minnesota
      • Rochester, Minnesota, Forente stater, 55905
        • Rekruttering
        • Mayo Clinic- Rochester
        • Ta kontakt med:
          • Anastasios Dimou, MD
          • Telefonnummer: 855-776-0015
    • New York
      • The Bronx, New York, Forente stater, 10461
        • Rekruttering
        • Montefiore Medical Center
        • Ta kontakt med:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15232
        • Rekruttering
        • University of Pittsburgh Medical Center - Hillman Cancer Center
        • Ta kontakt med:
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37203
        • Rekruttering
        • Tennessee Oncology
        • Ta kontakt med:
    • Virginia
      • Fairfax, Virginia, Forente stater, 22031
        • Rekruttering
        • Inova Schar Cancer Institute
        • Ta kontakt med:
      • Fairfax, Virginia, Forente stater, 22031
    • Washington
      • Seattle, Washington, Forente stater, 98109
        • Rekruttering
        • Fred Hutchinson Cancer Center/University of Washington
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Phase 2 Eligibility:

Key Inclusion Criteria Required for locally advanced or metastatic NSCLC:

  • Measurable disease by RECIST 1.1 criteria.

  • Adequate bone marrow or organ function.

  • Life expectancy of ≥ 3 months.

  • Sufficient performance status.

  • Confirmed NSCLC, without small cell lung cancer transformation with or without brain metastases.

  • Disease progression following or intolerance of standard of care (excluding patients in the treatment-naïve non-classical driver cohort):

    • Cohort 1 (Non-Classical driver cohort): Advanced/metastatic NSCLC with a non-classical driver EGFR mutation (eg, G719X) following up to 2 lines of therapy with only 1 prior EGFR TKI regimen (third-generation preferred; other approved EGFR TKI acceptable).
    • Cohort 2 (Acquired resistance C797S cohort): Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only one EGFR TKI, which must be a third generation EGFR TKI (eg, osimertinib).
    • Cohort 3 and 4 (First-line non-classical driver cohort): Treatment-naïve advanced/metastatic NSCLC with a non-classical driver EGFR mutations (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion.
  • Identification of one (or more) of the following EGFR mutations by Next Generation Sequencing (NGS) as determined by a local assay performed in a validated laboratory in the absence of other known resistance mutations (eg, T790M, MET):

    • Non-classical driver EGFR mutations (eg, L861R, S768I, G719X).
    • EGFR acquired resistance mutation (eg, C797S) to a 3rd generation EGFR TKI.
    • For Phase 2, dose expansion, patients in Cohort 1 who received 3rd generation EGFR TKI (eg, osimertinib), the NGS report within 6 months prior to the start of Screening is acceptable. For patients in Cohort 2, the NGS report must be from the last disease progression on the immediate prior therapy. For patients in Cohort 3 and 4, the NGS report must be at the time of diagnosis.

Key Exclusion Criteria:

  • Known resistant mutations in tumor tissue or by liquid biopsy (eg, T790M, MET).
  • Received more than 1 EGFR TKI therapy (ie, erlotinib or gefitinib) for the treatment of metastatic or recurrent EGFR NSCLC.
  • Any history of interstitial lung disease related to EGFR TKI use.
  • Symptomatic or radiographic leptomeningeal disease.
  • Symptomatic brain metastases or spinal cord compression requiring urgent clinical intervention.
  • Unresolved toxicity from prior therapy.
  • Significant cardiovascular disease.
  • Major surgery within 4 weeks of study entry or planned during study.
  • Ongoing or recent anticancer therapy or radiation therapy.
  • Evidence of malignancy (other than study-specific malignancies) requiring active therapy within the next 2 years.
  • Active hepatitis B or C infection and/or known human immunodeficiency virus (HIV) carrier.
  • Poorly controlled gastrointestinal disorders.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Phase 1 Dose Escalation - Monotherapy (Recruitment Closed)
  • Advanced/metastatic NSCLC with acquired resistance EGFR mutation (eg, C797S), following a 3rd generation EGFR inhibitor in the 1st line setting (in the absence of concurrent T790M).
  • Advanced/metastatic NSCLC with non-classical EGFR mutation (eg, G719X) following standard-of-care therapy with an EGFR inhibitor
  • Recurrent GBM with confirmed EGFR alterations (including amplification, mutation, and/or variant)

Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.

Andre navn:
  • BDTX-1535
Eksperimentell: Phase 2 Cohort 1: NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)

Advanced/metastatic NSCLC with a non-classical driver EGFR mutation following up to 2 lines of therapy with only 1 prior EGFR targeted regimen (third-generation preferred; other approved EGFR inhibitors acceptable)

Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.

Andre navn:
  • BDTX-1535
Eksperimentell: Phase 2 Cohort 2: NSCLC EGFR Acquired Resistance (C797S) Mutation (Recruitment Closed)

Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only 1 EGFR targeted regimen, which must be a third generation EGFR TKI (eg, osimertinib)

Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.

Andre navn:
  • BDTX-1535
Eksperimentell: Phase 2 Cohort 3: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)

Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 3 is 200 mg QD.

Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.

Andre navn:
  • BDTX-1535
Eksperimentell: Phase 2 Cohort 4: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations at 150 mg QD Dose

Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 4 is 150 mg QD.

Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.

Andre navn:
  • BDTX-1535

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535)
Tidsramme: The first treatment 21-day cycle (Cycle 1)

Dose-limiting toxicities (DLTs) in Cycle 1

The first treatment 21-day cycle (Cycle 1)
Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535)
Tidsramme: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)

Objective response rate (ORR) as assessed by Investigator using RECIST version 1.1

Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD dose
Tidsramme: Through study completion, approximately 1 year

Treatment-emergent adverse events

Through study completion, approximately 1 year

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Fase 2: For å vurdere progresjonsfri overlevelse ved RECIST versjon 1.1
Tidsramme: Dag 1 hver 2. syklus starter ved syklus 3 Dag 1 til studieavslutning, ca. 1 år (hver syklus er 21 dager)
Dag 1 hver 2. syklus starter ved syklus 3 Dag 1 til studieavslutning, ca. 1 år (hver syklus er 21 dager)
Fase 1: For å vurdere den foreløpige antitumoraktiviteten til silevertinib (BDTX-1535) ved objektiv respons som vurdert av RECIST versjon 1.1 (for pasienter med NSCLC) eller responsvurdering i nevro-onkologi (RANO) (for pasienter med GBM)
Tidsramme: Dag 1 hver 2 -syklus som starter på syklus 3 dag 1 for å studere fullføring, omtrent 1 år (hver syklus er 21 dager)
Dag 1 hver 2 -syklus som starter på syklus 3 dag 1 for å studere fullføring, omtrent 1 år (hver syklus er 21 dager)
Phase 2 Cohort 4 Only: To assess antitumor efficacy of silevertinib (BDTX-1535)
Tidsramme: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)

Objective response rate (ORR) as assessed by Investigator using RECIST version 1.1

Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Black Diamond Therapeutics, Black Diamond Therapeutics

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

31. mars 2022

Primær fullføring (Antatt)

1. mars 2028

Studiet fullført (Antatt)

1. juni 2028

Datoer for studieregistrering

Først innsendt

15. februar 2022

Først innsendt som oppfylte QC-kriteriene

24. februar 2022

Først lagt ut (Faktiske)

25. februar 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. november 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere